+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ALIVUS

Alivus Life Sciences Share Price

₹1,474.40 -84.3 (-5.41%)
New 52W High in past week

09 Nov, 2026 3:59 PM (IST)

Alivus Life Sciences live price: ₹1,474.40. It opened at ₹1,538 vs previous close ₹1,559; intraday high/low: ₹1,554/₹1,467. The 50 & 200 DMA stand at ₹1,370.90/₹1,200.40.

Alivus Life Sciences Performance

  • Today's Low
  • ₹1,467
  • Today's High
  • ₹1,554
  • 52 Week Low
  • ₹819
  • 52 Week High
  • ₹1,574
  • Open Price₹1,538
  • Previous Close₹1,559
  • Volume854,870
  • 50 DMA₹1,370.90
  • 100 DMA₹1,301.00
  • 200 DMA₹1,200.40

Alivus Life Sciences Chart

Investment Returns

  • Over 1 Month + 10.26%
  • Over 3 Month + 10.87%
  • Over 6 Month + 31.49%
  • Over 1 Year + 61.13%

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.1
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 18,130
  • P/B Ratio
  • 5.2
  • Average True Range
  • 70.3
  • EPS
  • 54.5
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 43.8
  • RSI
  • 58.41
  • MFI
  • 60.21

Latest Stock News Updates

Alivus Life Sciences Ltd - 543322 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Please find attached herewith submission with respect to transcript of the earning call.

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Please find enclosed herewith intimation for Analyst/Investor meeting.

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,474.40
-84.3 (-5.41%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹1,420.00
  • 50 Day
  • ₹1,370.90
  • 100 Day
  • ₹1,301.00
  • 200 Day
  • ₹1,200.40

Resistance and Support

1498.3 Pivot Speed
  • R3 1,617.60
  • R2 1,585.80
  • R1 1,530.10
  • S1 1,442.60
  • S2 1,410.80
  • S3 1,355.10

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-29 Quarterly Results
2026-07-30 Quarterly Results
2026-05-14 Audited Results & Final Dividend
2026-01-22 Quarterly Results
2025-11-06 Quarterly Results
Date Purpose Remarks
2026-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2025-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View Alivus Life Sciences Dividend History Arrow

Alivus Life Sciences Shareholding Pattern

74.85%
12.19%
5.93%
5.29%
1.74%

About Alivus Life Sciences

Alivus Life Sciences is primarily engaged in the development, manufacture, and marketing of active pharmaceutical ingredients. View More
  • NSE Symbol
  • ALIVUS
  • BSE Symbol
  • 543322
  • Executive Director,Managing Director,Chief Executive Officer
  • Yasir Yusufali Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Alivus Life Sciences

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,474 As on 10 November, 2026 | 02:52

The Market Cap of Alivus Life Sciences is ₹18130.3 Cr As on 10 November, 2026 | 02:52

The P/E ratio of Alivus Life Sciences is 27.1 As on 10 November, 2026 | 02:52

The PB ratio of Alivus Life Sciences is 5.2 As on 10 November, 2026 | 02:52

The 52 week High & Low of Alivus Life Sciences is ₹1574/₹819 respectively As on 10 November, 2026 | 02:52

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23